Agios Pharm
$ 28.29
-1.74%
05 Jun - close price
- Market Cap 1,682,452,000 USD
- Current Price $ 28.29
- High / Low $ 29.39 / 28.13
- Stock P/E N/A
- Book Value 18.69
- EPS -7.26
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.33 %
- 52 Week High 46.00
- 52 Week Low 22.24
About
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$40.88
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -1.69 | -1.85 | -1.78 | -1.93 | -1.55 | -1.74 | -1.47 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 |
| Estimated EPS | -1.79 | -1.95 | -1.9 | -1.75 | -1.76 | -1.63 | 7.91 | -1.61 | -1.68 | -1.64 | -1.64 | -1.5 |
| Surprise | 0.1 | 0.1 | 0.12 | -0.18 | 0.21 | -0.11 | -9.38 | -0.08 | 0.23 | -0.08 | 0 | -0.01 |
| Surprise Percentage | 5.5866% | 5.1282% | 6.3158% | -10.2857% | 11.9318% | -6.7485% | -118.5841% | -4.9689% | 13.6905% | -4.878% | 0% | -0.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.75 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGIO
2026-06-05 15:39:59
Agios Pharmaceuticals (AGIO) saw a 5.4% stock price drop after recent strategic updates to its hematology portfolio, including ceasing development of tebapivat in lower-risk myelodysplastic syndromes, gaining European approval for PYRUKYND in thalassemia, and licensing cevidoplenib from Oscotec. These changes reshape the company's product mix, focusing on mitapivat as its core rare-disease asset. The European approval for PYRUKYND is a significant commercial step, though potential hepatotoxicity concerns could impact its market adoption, leading to investor caution despite analyst forecasts of substantial revenue growth.
2026-06-04 09:39:06
Agios Pharmaceuticals (AGIO) stock is in focus after the company signed an exclusive global licensing agreement for cevidoplenib. Despite a recent share price increase, the stock is still down 18.66% over the last year, with an annual revenue of US$66.05 million and a net loss of US$422.60 million. The article explores whether the cevidoplenib deal and potential FDA approval for PYRUKYND represent a genuine upside for the stock, with fair value estimates significantly higher than the current price, though other indicators suggest valuation risk.
2026-06-04 08:35:41
Agios Pharmaceuticals (AGIO) recently signed a licensing agreement for cevidoplenib, affecting its stock valuation. While the share price saw a 4.41% increase in one day, its 1-year total shareholder return is down 18.66%. The market is split on whether the recent excitement is a genuine growth opportunity or if future growth is already priced in, with different narratives suggesting fair values around $40.88 versus a P/S ratio that looks stretched compared to industry averages.
2026-06-04 08:10:20
Oscotec announced that Agios Pharmaceuticals plans to start a Phase 3 trial for cevidoplenib, its SYK inhibitor for immune thrombocytopenia (ITP), in the first half of 2028, targeting approval and commercialization before 2030. This development follows a licensing deal worth up to $665 million. Oscotec CEO Yoon Tae-young highlighted the drug's potential for relatively quick milestone flows due to ITP being a rare disease and emphasized cevidoplenib's tolerability advantages over existing treatments.
2026-06-02 14:10:17
Agios Pharmaceuticals (AGIO) has acquired exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a late-stage oral SYK inhibitor for immune thrombocytopenia (ITP). This deal expands Agios' rare hematology portfolio, adding a potential treatment for ITP with an estimated annual U.S. sales potential of up to $1 billion. Despite the strategic acquisition, AGIO shares saw a decline due to investor concerns over a recent discontinuation of another drug candidate.
2026-06-01 21:39:59
Agios Pharmaceuticals has discontinued the development of tebapivat for lower-risk myelodysplastic syndromes due to a Phase 2b trial not meeting efficacy targets. This decision shifts investor focus to Agios's remaining pipeline, particularly its sickle cell disease program, and raises questions about capital reallocation and future trial execution. The stock's performance reflects past pipeline expectations, with recent gains but longer-term declines.
